Aspira Pathlab's board has approved the financial results for the first quarter ended June 30, 2025. Standalone revenue from operations was ₹5.25 Cr, with a profit after tax of ₹0.07 Cr.

AP

Aspira Pathlab & Diagnostics Ltd540788 · Filed with the exchange

On a consolidated basis, revenue from operations was ₹5.25 Cr, reporting a profit after tax of ₹0.42 Cr.

The company also acquired Aspira DNA Diagnostics Gujarat LLP on a slump sale basis for ₹0.13 Cr, effective June 30, 2025. Additionally, Dr. Alaka Keshav Deshpande was appointed as an Additional Woman Independent Director, subject to shareholder approval.

Read the original filing(PDF)

No comments yet. Be the first.

More from Aspira Pathlab & Diagnostics Ltd

All announcements

Board Meeting07-09-2026
Board Meeting
Important01-09-2026
Company Update
Important01-09-2026
Company Update
Others31-08-2026
Others
Others31-08-2026
AGM/EGM
Dividend/Bonus31-08-2026
Corp. Action

Free

Track this company, and every filing it makes

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

Create a free account

No card needed. Takes about a minute.